If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

Discovery Report
The Future of
Bacteria may fuel the next global pandemic. Will we be ready?
Illustration by Chris Gash

After commercial antibiotics emerged in the early 20th century, we began to take for granted the ability to treat bacterial infections. But as bacteria evolved to resist those drugs, pharmaceutical companies have struggled to develop new drugs to challenge the microbes. As a result, the world is facing a public health crisis of drug-resistant bacterial infections.

In this Discovery Report, you’ll meet the scientists and companies working on the cutting edge of antibiotic drug discovery and antimicrobial science. You’ll hear from experts involved in pharmaceutical economics about pilot programs to change the way antibiotics are paid for. You’ll read about the path of one antibiotic, Nabriva Therapeutics’ Xenleta (lefamulin) from discovery to market.

Log in with your ACS ID or create an account to read this Discovery Report. LOG IN NOW TO READ

ACS paid members get instant access to Discovery Reports. Become a paid member and you'll be the first to receive our analysis on key trends. BECOME A MEMBER


This article has been sent to the following recipient: